Atea Pharmaceuticals, Inc.
AVIR
$5.27
-$0.41-7.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -31.57% | -13.58% | |||
| Gross Profit | 31.57% | 13.58% | |||
| SG&A Expenses | 1.09% | -3.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.89% | -12.25% | |||
| Operating Income | 26.89% | 12.25% | |||
| Income Before Tax | 27.50% | 12.09% | |||
| Income Tax Expenses | -52.00% | 100.74% | |||
| Earnings from Continuing Operations | 27.52% | -1.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.52% | -1.28% | |||
| EBIT | 26.89% | 12.25% | |||
| EBITDA | 26.95% | 12.28% | |||
| EPS Basic | 28.30% | 0.09% | |||
| Normalized Basic EPS | 28.28% | 12.91% | |||
| EPS Diluted | 28.30% | 0.09% | |||
| Normalized Diluted EPS | 28.28% | 12.91% | |||
| Average Basic Shares Outstanding | 1.08% | 1.37% | |||
| Average Diluted Shares Outstanding | 1.08% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||